top of page
November 2025
August 2025
January 2025
Novastra Therapeutics Provides Clinical Update on Emerging Clinical Data from OAP-101 Phase 1b Trial. Demonstrates Safety and Immune Activation in Refractory Solid Tumors.
Novastra Therapeutics Secures Competitive Non-Dilutive Grant Funding to Accelerate OmniAntigen™ Platform.
First Patient Dosed in OAP-101
First-in-Human Clinical Trial.
bottom of page